Provided by Tiger Trade Technology Pte. Ltd.

Ironwood Pharmaceuticals

4.13
+0.29007.55%
Post-market: 4.11-0.0200-0.48%19:56 EDT
Volume:7.11M
Turnover:29.11M
Market Cap:679.85M
PE:6.91
High:4.17
Open:3.79
Low:3.79
Close:3.84
52wk High:5.78
52wk Low:0.6701
Shares:164.61M
Float Shares:127.00M
Volume Ratio:2.88
T/O Rate:5.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5973
EPS(LYR):0.1484
ROE:-574.72%
ROA:33.15%
PB:-3.13
PE(LYR):27.83

Loading ...

Ironwood Pharmaceuticals Inc - Sees 2026 U.S. Linzess Net Sales $1.125-$1.175 Bln

THOMSON REUTERS
·
May 07

Ironwood Pharmaceuticals Q1 Basic EPS USD 0.25

THOMSON REUTERS
·
May 07

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year Linzess U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

THOMSON REUTERS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06

Ironwood Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview

Reuters
·
May 05

Ironwood survey finds SBS clinicians prioritize fewer TPN days in future therapies

Reuters
·
May 04

Ironwood Pharmaceuticals to host first-quarter investor update call and webcast

Reuters
·
May 01

Ironwood to present long-term STARS trial safety data for apraglutide in SBS-IF

Reuters
·
Apr 23

Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)

TIPRANKS
·
Mar 19

Ironwood Pharmaceuticals director Alexander J. Denner disposes of shares worth USD 20.53 million

Reuters
·
Mar 18

BRIEF-Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10

Reuters
·
Mar 11

Ironwood Pharmaceuticals Inc - Maturity Date for Revolving Credit Facility Remains December 31, 2028 - SEC Filing

THOMSON REUTERS
·
Mar 11

Ironwood Pharmaceuticals extends revolving credit facility maturity to Dec. 31, 2028

Reuters
·
Mar 11

Ironwood Pharmaceuticals to Join Fireside Chat at The Citizens Life Sciences Conference

Reuters
·
Mar 05

Ironwood Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Feb 26

Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks

TIPRANKS
·
Feb 26

Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate

Benzinga
·
Feb 25

BRIEF-Ironwood Pharmaceuticals Q4 Revenue USD 47.709 Million

Reuters
·
Feb 25

Ironwood Pharmaceuticals Inc: Reiterates 2026 Outlook

THOMSON REUTERS
·
Feb 25

Ironwood Pharmaceuticals Q4 Adjusted Net Income USD -2.274 Million

THOMSON REUTERS
·
Feb 25